ijms-logo

Journal Browser

Journal Browser

Exploring the Molecular Mechanisms of Chronic Kidney Disease

Special Issue Editor


E-Mail Website
Guest Editor
Vascular and Renal Translational Research Group, Biomedical Research Institute of Lleida (IRBLleida), Arnau de Vilanova University Hospital, 25198 Lleida, Spain
Interests: bone disease; mineral metabolism; renal disease; vascular calcification; calcium-sensing receptor; fibroblast growth factor 23; sclerostin; vitamin D; parathyroid hormone
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic kidney disease (CKD) is a global challenge, currently affecting approximately 1 in 10 individuals, accounting for over 800 million people with CKD worldwide. Unfortunately, the prevalence of CKD is increasing, estimated to become the fifth leading cause of death by 2040, which underscores the significant social and economic impact of this devastating disease. Research efforts focus on the prevention of CKD progression and associated complications that usually lead to increased hospitalization and higher mortality risk. Understanding the distinct molecular mechanisms underlying CKD development is key for identifying new therapeutic approaches and achieving the optimization of patient care.

This Special Issue aims to compile cutting-edge research on the molecular features of renal diseases and CKD-associated disorders, including metabolic bone disease, anemia, cardiovascular disease, diabetes and hypertension. In addition, novel molecular actions of current treatments and emerging drugs, as well as future strategies for preventing complications associated with dialysis or renal transplantation are also included.

Dr. Juan Miguel Diaz-Tocados
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic kidney disease
  • hereditary renal disease
  • renal hypertension
  • diabetic nephropathy
  • secondary hyperparathyroidism
  • cardiovascular disease
  • renal osteodystrophy
  • peritoneal dialysis
  • hemodialysis
  • anemia
  • metabolic acidosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 2365 KiB  
Article
Citrate Dialysate with and without Magnesium Supplementation in Hemodiafiltration: A Comparative Study Versus Acetate
by Diana Rodríguez-Espinosa, Elena Cuadrado-Payán, Naira Rico, Mercè Torra, Rosa María Fernández, Gregori Casals, María Rodríguez-García, Francisco Maduell and José Jesús Broseta
Int. J. Mol. Sci. 2024, 25(15), 8491; https://doi.org/10.3390/ijms25158491 - 3 Aug 2024
Cited by 1 | Viewed by 969
Abstract
The choice of dialysate buffer in hemodialysis is crucial, with acetate being widely used despite complications. Citrate has emerged as an alternative because of its favorable effects, yet concerns persist about its impact on calcium and magnesium levels. This study investigates the influence [...] Read more.
The choice of dialysate buffer in hemodialysis is crucial, with acetate being widely used despite complications. Citrate has emerged as an alternative because of its favorable effects, yet concerns persist about its impact on calcium and magnesium levels. This study investigates the influence of citrate dialysates (CDs) with and without additional magnesium supplementation on CKD-MBD biomarkers and assesses their ability to chelate divalent metals compared to acetate dialysates (ADs). A prospective crossover study was conducted in a single center, involving patients on thrice-weekly online hemodiafiltration (HDF). The following four dialysates were compared: two acetate-based and two citrate-based. Calcium, magnesium, iPTH, iron, selenium, cadmium, copper, zinc, BUN, albumin, creatinine, bicarbonate, and pH were monitored before and after each dialysis session. Seventy-two HDF sessions were performed on eighteen patients. The CDs showed stability in iPTH levels and reduced post-dialysis total calcium, with no significant increase in adverse events. Magnesium supplementation with CDs prevented hypomagnesemia. However, no significant differences among dialysates were observed in the chelation of other divalent metals. CDs, particularly with higher magnesium concentrations, offer promising benefits, including prevention of hypomagnesemia and stabilization of CKD-MBD parameters, suggesting citrate as a viable alternative to acetate. Further studies are warranted to elucidate long-term outcomes and optimize dialysate formulations. Until then, given our results, we recommend that when a CD is used, it should be used with a 0.75 mmol/L Mg concentration rather than a 0.5 mmol/L one. Full article
(This article belongs to the Special Issue Exploring the Molecular Mechanisms of Chronic Kidney Disease)
Show Figures

Figure 1

Review

Jump to: Research

21 pages, 4656 KiB  
Review
Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models
by Luka Varda, Robert Ekart, Mitja Lainscak, Uroš Maver and Sebastjan Bevc
Int. J. Mol. Sci. 2024, 25(16), 9088; https://doi.org/10.3390/ijms25169088 - 22 Aug 2024
Viewed by 1158
Abstract
Mineralocorticoid receptor antagonists (MRAs) are one of the renin–angiotensin–aldosterone system inhibitors widely used in clinical practice. While spironolactone and eplerenone have a long-standing profile in clinical medicine, finerenone is a novel agent within the MRA class. It has a higher specificity for mineralocorticoid [...] Read more.
Mineralocorticoid receptor antagonists (MRAs) are one of the renin–angiotensin–aldosterone system inhibitors widely used in clinical practice. While spironolactone and eplerenone have a long-standing profile in clinical medicine, finerenone is a novel agent within the MRA class. It has a higher specificity for mineralocorticoid receptors, eliciting less pronounced adverse effects. Although approved for clinical use in patients with chronic kidney disease and heart failure, intensive non-clinical research aims to further elucidate its mechanism of action, including dose-related selectivity. Within the field, animal models remain the gold standard for non-clinical testing of drug pharmacological and toxicological properties. Their role, however, has been challenged by recent advances in in vitro models, mainly through sophisticated analytical tools and developments in data analysis. Currently, in vitro models are gaining momentum as possible platforms for advanced pharmacological and pathophysiological studies. This article focuses on past, current, and possibly future in vitro cell models research with clinically relevant MRAs. Full article
(This article belongs to the Special Issue Exploring the Molecular Mechanisms of Chronic Kidney Disease)
Show Figures

Figure 1

Back to TopTop